In the last trading session, 1.55 million Immuneering Corp (NASDAQ:IMRX) shares changed hands as the company’s beta touched -0.48. With the company’s per share price at $2.66 changed hands at $0.05 or 1.92% during last session, the market valuation stood at $78.87M. IMRX’s last price was a discount, traded about -238.35% off its 52-week high of $9.00. The share price had its 52-week low at $1.00, which suggests the last value was 62.41% up since then. When we look at Immuneering Corp’s average trading volume, we note the 10-day average is 15.18 million shares, with the 3-month average coming to 6.24 million.
Analysts gave the Immuneering Corp (IMRX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.57. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended IMRX as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Immuneering Corp’s EPS for the current quarter is expected to be -0.55.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Immuneering Corp (NASDAQ:IMRX) trade information
Instantly IMRX was in green as seen at the end of in last trading. With action -17.13%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -63.81%, with the 5-day performance at -17.13% in the red. However, in the 30-day time frame, Immuneering Corp (NASDAQ:IMRX) is 135.40% up. Looking at the short shares, we see there were 3.02 million shares sold at short interest cover period of 0.43 days.
The consensus price target for the stock as assigned by Wall Street analysts is 13, meaning bulls need an upside of 79.54% from its current market value. According to analyst projections, IMRX’s forecast low is 3 with 41 as the target high. To hit the forecast high, the stock’s price needs a -1441.35% plunge from its current level, while the stock would need to soar -12.78% for it to hit the projected low.
Immuneering Corp (IMRX) estimates and forecasts
Data shows that the Immuneering Corp share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -7.96% over the past 6 months, a -0.53% in annual growth rate that is considerably lower than the industry average of 17.70%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -57.97%. The 2024 estimates are for Immuneering Corp earnings to decrease by -0.30%.
IMRX Dividends
Immuneering Corp is expected to release its next quarterly earnings report in October.
Immuneering Corp (NASDAQ:IMRX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 29.17% of Immuneering Corp shares while 32.51% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 45.90%. There are 32.51% institutions holding the Immuneering Corp stock share, with CITADEL ADVISORS LLC the top institutional holder. As of 2024-06-30, the company held 6.4083% of the shares, roughly 1.88 million IMRX shares worth $2.41 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 3.6442% or 1.07 million shares worth $1.37 million as of 2024-06-30.
